LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Consensus Target Price from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $94.57.

Several research analysts have commented on LMAT shares. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NBC Securities Inc. raised its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares in the last quarter. USA Financial Formulas bought a new position in shares of LeMaitre Vascular in the third quarter valued at approximately $60,000. GAMMA Investing LLC raised its position in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 188 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $82,000. Finally, Acadian Asset Management LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $104,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 0.6 %

NASDAQ:LMAT opened at $99.65 on Friday. LeMaitre Vascular has a twelve month low of $56.04 and a twelve month high of $109.58. The company has a 50-day moving average of $98.35 and a 200-day moving average of $92.07. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period last year, the company posted $0.33 earnings per share. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. On average, research analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.64%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s payout ratio is presently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.